[Source: US Centers for Disease Control and Prevention (CDC), Emerging Infectious Diseases Journal, full page: (LINK). Abstract, edited.]
Volume 25, Number 4—April 2019 / Research Letter
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
Yacine Abed1, Clément Fage1, Patrick Lagüe, Julie Carbonneau, Jesse Papenburg, Donald C. Vinh, and Guy Boivin
Author affiliations: Laval University, Québec City, Québec, Canada (Y. Abed, C. Fage, P. Lagüe, J. Carbonneau, G. Boivin); Montreal Children’s Hospital, Montreal, Québec (J. Papenburg); McGill University Health Center, Montreal (D.C. Vinh)
We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.
Keywords: Seasonal Influenza; Influenza B; Antivirals; Drugs Resistance; Oseltamivir; Zanamivir; Peramivir; Canada.